EMA And FDA Eliminating ‘Needless Differences’ – Particularly For Rare Diseases

US and EU regulators have invited two companies to work with them on a pilot scheme for assessing drugs for rare genetic diseases, a move that the European Medicines Agency’s Emer Cooke said would help improve “global alignment.”